Kyno (Minocycline Hydrochloride)

Minocycline Hydrochloride is employed to treat bacterial infections across several organ systems, targeting pathogens that are susceptible to tetracycline antibiotics.

• Acne vulgaris: reduces inflammatory lesions and bacterial colonisation of the skin.
• Skin and soft tissue infections: eradicates susceptible bacteria and promotes healing of cellulitis and abscesses.
• Respiratory tract infections: treats community‑acquired pneumonia and bronchitis caused by susceptible organisms.
• Urinary tract infections: eliminates common uropathogens and relieves symptoms of uncomplicated cystitis.

• Minocycline Hydrochloride binds to the 30S ribosomal subunit of susceptible bacteria, blocking the attachment of aminoacyl‑tRNA to the mRNA‑ribosome complex. This inhibition prevents the addition of new amino acids to the growing peptide chain, thereby halting bacterial protein synthesis and leading to a bacteriostatic effect against a broad range of Gram‑positive and Gram‑negative organisms.

Adverse reactions may occur with minocycline therapy and should be monitored.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Photosensitivity: increased skin sensitivity to sunlight.
• Dizziness: transient light‑headedness.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.
• Drug‑induced hepatitis: elevated liver enzymes and jaundice.
• Pseudotumor cerebri: increased intracranial pressure causing headache and visual changes.
• Severe hypersensitivity: anaphylaxis or angioedema.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Renal function: adjust use in patients with impaired kidney function.
• Hepatic function: monitor liver enzymes during prolonged treatment.
• Hypersensitivity: avoid in individuals with known allergy to tetracyclines.
• Photosensitizing agents: use caution when combined with other photosensitizers.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Minocycline may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Isotretinoin: increased risk of pseudotumor cerebri.
• Oral anticoagulants: enhanced anticoagulant effect and bleeding risk.
• Antacids containing aluminum or magnesium: reduced minocycline absorption.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: decreased hormonal efficacy, consider backup method.
• Cyclosporine: possible increase in cyclosporine levels.
• Methotrexate: heightened risk of toxicity, monitor blood counts and liver function.